Biomedical subjects

P Albertini

Publications and source records attributed to P Albertini.

21 records · Page 2Linked to original sources

PubMed1989

Effect of acetyl-L-carnitine treatment on the density of muscarinic receptors in the brain of methylazoxymethanol-microencephalic rats.

The effect of methylazoxymethanol (MAM), administered on the 15th gestational day, on the density and pattern of muscarinic cholinergic receptors in some brain areas was assessed using combined radioreceptor binding and autoradiographic techniques. The effect of 15 days' treatment with acetyl-L-carnitine on the same parameter was also assessed. The density of muscarinic cholinergic receptors was found to be increased in the brain of MAM-microencephalic rats. Acetyl-L-carnitine administration caused a significant reduction in the density of receptors under study. A possible role of acetyl-L-carnitine in restoring central cholinergic neurotransmission is discussed.

Acetylcarnitine↗

PubMed1989

Effect of acetyl-L-carnitine treatment on brain ribonucleic acid levels in methylazoxymethanol-microencephalic rats.

The effects of methylazoxymethanol acetate (MAM) administered on the 15th gestational day, and of acetyl-L-carnitine treatment, on rat brain total and ribosomal RNA levels, were studied. In the brain of MAM-treated rats both total and ribosomal RNA concentrations were significantly reduced. Acetyl-L-carnitine treatment restored total and ribosomal RNA levels. The frontal cortex and the hippocampus were the brain areas most sensitive to acetyl-L-carnitine administration. Histochemical demonstration of tissue stores of nucleic acids showed that the loss of RNA induced by MAM occurs primarily within the cytoplasm of nerve cells in various telencephalic areas. Neuronal cytoplasmatic RNA is also sensitive to acetyl-L-carnitine treatment.

Acetylcarnitine↗

PubMedDate not supplied

MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results.

A single-center, retrospective study was conducted to evaluate therapeutic results of the MACOP-B third-generation chemotherapy regimen followed by involved-field radiation therapy in a stage I-II aggressive non-Hodgkin's lymphoma (NHL) patients. From 1986 to 1995, 118 consecutive patients with the diagnosis of aggressive NHL, stage I-IE or II-IIE, with or without bulky disease were treated with MACOP-B regimen followed, when appropriate, by 30-36 Gy involved-field radiation therapy. The complete response (CR) rate was 95% after the combined modality treatment (97% for stage I-IE and 93% for stage II-IIE). Patients with bulky disease had a CR rate of 92%. Treatment was well tolerated and no deaths occurred from acute toxicity. After a median follow-up of 68 months, 24 (21%) patients relapsed. The 14-year projected relapse-free and overall survival rates were 78% and d 69%, respectively. MACOP-B regimen with/without involved-field radiation therapy provides a safe and effective combined modality treatment for early-stage aggressive NHL, with the possibility to definitively cure two thirds of the patients.

Adolescent↗